Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RHYTHM PHARMACEUTICALS, INC. Director's Dealing 2019

Feb 20, 2019

30849_dirs_2019-02-20_61a8b67b-7e12-4563-931b-87c7e420a99d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2019-02-15

Reporting Person: Gottesdiener Keith Michael (Director, CEO and President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-02-15 Common Stock S 12002 $30.02 Disposed 528984 Direct
2019-02-19 Common Stock S 918 $30.05 Disposed 528066 Direct

Footnotes

F1: On February 15, 2019, Mr. Gottesdiener sold 12,002 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.18, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: On February 19, 2019, Mr. Gottesdiener sold 918 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.